Rui Yang joined Novartis in 2021, where his primary focus was on breast cancer HCP marketing. He counts his work on metastatic breast cancer drug Kisqali as among his greatest accomplishments. Yang led the omnichannel promotion strategy as he and his team launched more than 10 first-in-class marketing programs that drove personalization, innovation, speed to market and multi-touchpoint deep engagement. Under his leadership, targeted unique HCP omnichannel engagement has increased 200%, a significant contribution to the brand business. In January, he was elevated to director of marketing strategy — oncology.

Prior to Novartis, Yang worked in consumer healthcare and was the brand lead for Enfamil’s Nutramigen, an infant allergy specialty formula manufactured by Reckitt. He led the marketing effort for the business turnaround.

Yang serves as an adjunct professor of marketing at NYU’s Stern School of Business and as an advisory board member at Harvard Business Review. Outside of work, Yang seeks out opportunities to escape to the great outdoors, spending his free time hiking and camping.

Click here to return to the 2024 MM+M 40 Under 40 homepage.